Rogerio C. Lilenbaum, MD Appointed Chief Medical Officer of Smilow Cancer Hospital at Yale-New Haven

New Haven, Conn. — The leadership of Smilow Cancer Hospital at Yale-New Haven is delighted to announce the appointment of Rogerio C. Lilenbaum, MD to the position of Chief Medical Officer of the hospital.  Dr. Lilenbaum is currently Chairman of the Cancer Institute at the Cleveland Clinic in Florida and will begin his tenure at Smilow on January 1, 2013.  Dr. Lilenbaum is a practicing medical oncologist and will also care for patients through the Thoracic Oncology Program.


“Dr. Lilenbaum’s life has been about caring for patients with lung cancer.  He has done pioneering work in defining the best way to treat lung cancer—particularly in older patients.  He is a proven leader who is committed to enhancing Smilow Cancer Hospital’s ability to provide the very best care to our patients.   I look forward to working with him to ensure we provide the highest quality care to our patients,” said Dr. Thomas J. Lynch, Jr., Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven.


Prior to joining the Cleveland Clinic in 2011, Dr. Lilenbaum was the Director of Cancer Research and Director of the Thoracic Oncology Program at Mount Sinai Medical Center, in Miami Beach, Florida. He also served as the Principal Investigator of the Mount Sinai Community Clinical Oncology Program (CCOP).


“Yale Cancer Center, under the leadership of Dr. Lynch, has become one of the most prominent programs in the country, and I am honored by the opportunity to join such a distinguished faculty.  I look forward to working with the leadership of Smilow Cancer Hospital to contribute to its mission of excellence in patient care,” Dr. Lilenbaum said.


Dr. Lilenbaum is a member of the Thoracic Malignancy Steering Committee of the National Cancer Institute, the American Society of Clinical Oncology (ASCO) Cancer Research Committee, on whose behalf he chairs the Community Research Forum, the Alliance Respiratory Core Committee, and is consistently named as one of “America’s Top Physicians” and “America’s Top Oncologists.”  He has authored more than 100 peer-reviewed papers and book chapters related to lung cancer.


Dr. Lilenbaum received his medical degree from the Federal University of Rio de Janeiro School of Medicine in Brazil and earned a masters degree in clinical epidemiology and clinical investigation from the Harvard School of Public Health.  He completed his hematology/oncology fellowship at Washington University School of Medicine and a clinical and research fellowship at the University of California San Diego. 


Yale Cancer Center is one of a select network of 41 comprehensive cancer centers in the country designated by the National Cancer Institute. Bringing together the resources of Smilow Cancer Hospital at Yale-New Haven and the Yale School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.


Smilow Cancer Hospital at Yale-New Haven is part of Yale-New Haven Hospital and is affiliated with Yale Cancer Center. Smilow Cancer Hospital, the most comprehensive cancer facility in New England, is a 14-story, 500,000-square-foot cancer hospital, which includes: 168 private inpatient rooms, outpatient multidisciplinary treatment centers, 12 operating rooms, infusion suites, diagnostic imaging services, a floor for children with cancer, a specialized women's cancer center and diagnostic and therapeutic radiology services for children and adults.

Appointments:  (203) 200-5864     

Administrative Office:  (203) 200-1344

This article was submitted by Renee Elizabeth Gaudette on November 20, 2012.